In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. The sector contributed significantly to the country's bio-economy, valued at over $150 billion, as government policies and initiatives bolstered innovation and sustainable development.
